ATE326239T1 - Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren - Google Patents

Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren

Info

Publication number
ATE326239T1
ATE326239T1 AT99948333T AT99948333T ATE326239T1 AT E326239 T1 ATE326239 T1 AT E326239T1 AT 99948333 T AT99948333 T AT 99948333T AT 99948333 T AT99948333 T AT 99948333T AT E326239 T1 ATE326239 T1 AT E326239T1
Authority
AT
Austria
Prior art keywords
methods
compositions
treating
ige
associated diseases
Prior art date
Application number
AT99948333T
Other languages
English (en)
Inventor
Dino Dina
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Application granted granted Critical
Publication of ATE326239T1 publication Critical patent/ATE326239T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99948333T 1998-09-18 1999-09-17 Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren ATE326239T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10083898P 1998-09-18 1998-09-18
US13660099P 1999-05-28 1999-05-28
US39719899A 1999-09-16 1999-09-16

Publications (1)

Publication Number Publication Date
ATE326239T1 true ATE326239T1 (de) 2006-06-15

Family

ID=27379083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948333T ATE326239T1 (de) 1998-09-18 1999-09-17 Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren

Country Status (9)

Country Link
US (2) US20030064064A1 (de)
EP (1) EP1113818B1 (de)
JP (1) JP2003524602A (de)
AT (1) ATE326239T1 (de)
AU (1) AU766492B2 (de)
CA (1) CA2343052A1 (de)
DE (1) DE69931377T2 (de)
ES (1) ES2259478T3 (de)
WO (1) WO2000016804A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1674574A1 (de) * 1998-05-14 2006-06-28 Coley Pharmaceutical GmbH Verfahren zur Regulierung der Hematopoiese mit Hilfe von CpG Oligonukleotide
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
EP1278550A4 (de) * 2000-04-07 2004-05-12 Univ California Synergistische verbesserungen von polynucleotid impfstoffen
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
DE60142410D1 (de) 2000-12-27 2010-07-29 Dynavax Tech Corp Immunomodulatorische polynukleotide und verfahren zur deren verwendung
WO2002092125A1 (en) * 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
EP2107110A3 (de) * 2001-05-15 2011-10-26 Ortho-McNeil Pharmaceutical, Inc. Ex-vivo-Priming zur Erzeugung zytotoxischer T-Lymphozyten, die für Nicht-Tumorantigene spezifisch sind, zur Behandlung von Autoimmunerkrankungen und Allergien
US20030199466A1 (en) 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002324124B2 (en) * 2001-08-16 2007-01-04 Mucovax Inc. Chitin microparticles and their medical uses
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
DE60329223D1 (de) * 2002-12-23 2009-10-22 Dynavax Tech Corp Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
WO2006080946A2 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
JP2008531722A (ja) 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション 構造的に安定なコンジュゲート分子を含む組成物
KR20080008350A (ko) * 2005-04-08 2008-01-23 콜레이 파마시티컬 그룹, 인코포레이티드 감염성 질환에 의해 악화된 천식의 치료 방법
JP5473336B2 (ja) * 2006-02-15 2014-04-16 アディウタイド・ファーマスーティカルズ・ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
SG11201501011WA (en) 2012-09-07 2015-03-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
EP3110848B1 (de) 2014-02-28 2024-02-14 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung einer hautinfektion durch verabreichung eines il-4r-antagonisten
KR20170081262A (ko) 2014-11-14 2017-07-11 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
US10384291B2 (en) * 2015-01-30 2019-08-20 Lincoln Global, Inc. Weld ending process and system
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
JP7315545B2 (ja) 2017-10-30 2023-07-26 サノフィ・バイオテクノロジー Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
MX2022000649A (es) 2019-07-16 2022-06-08 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US280005A (en) * 1883-06-26 baldwin
US2676325A (en) * 1952-08-02 1954-04-27 Carlson Julius Cap construction
US4491632A (en) * 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US5015733A (en) * 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5026545A (en) * 1984-09-17 1991-06-25 Baxter International, Inc. Treatment of allergy and composition therefor
US4633530A (en) * 1985-09-04 1987-01-06 Satterfield Roy E Protective device
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5614611A (en) * 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5422258A (en) * 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5121507A (en) * 1990-10-10 1992-06-16 Brown Ronald R Headwear accessory attachment
US5125113A (en) * 1991-04-30 1992-06-30 Yun In Seo Visored cap with front, side and rear shades
CA2086605A1 (en) * 1991-05-10 1992-11-11 Alain De Weck Procedure for detecting and preparing anti-ige autoantibodies and use of these antibodies as active agents in diagnostic and therapeutic compositions
US5153943A (en) * 1991-09-04 1992-10-13 Clement Keith H Weather-shield hat accessory
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
MX9602818A (es) * 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
US5426790A (en) * 1994-02-25 1995-06-27 Robertson; Stanley Sun shield for head wear
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT772619E (pt) * 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US5493733A (en) * 1994-09-09 1996-02-27 Pospisil; Robert L. Cap providing sun protection for ears
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
CA2281838A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6079052A (en) * 1999-07-19 2000-06-27 Veridiano; Carlos H. Headgear with removable forwardly extending side flaps
US6550064B2 (en) * 2001-01-17 2003-04-22 Robert Schmitt Ear shield apparatus

Also Published As

Publication number Publication date
EP1113818A1 (de) 2001-07-11
AU6153799A (en) 2000-04-10
DE69931377T2 (de) 2007-05-10
AU766492B2 (en) 2003-10-16
ES2259478T3 (es) 2006-10-01
WO2000016804A1 (en) 2000-03-30
CA2343052A1 (en) 2000-03-30
JP2003524602A (ja) 2003-08-19
US20060013811A1 (en) 2006-01-19
DE69931377D1 (de) 2006-06-22
EP1113818B1 (de) 2006-05-17
US20030064064A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
BRPI0211200B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE69833779D1 (de) Verfahren und zusammensetzungen zur immunomodulation
ATE277612T1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE440618T1 (de) Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
ATE304350T1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
BR9808606A (pt) Materiais e métodos para tratamento de doenças com ribozimas
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
ATE287713T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1113818

Country of ref document: EP